Abstract: Provided are an Akkermansia muciniphila strain and use thereof in preventing and treating metabolic diseases. This strain is named Akkermansia muciniphila SSYD-3 and the accession number thereof is CGMCC No. 14764. This strain is more ideal than the existing Akkermansia strain ATCC BAA835 in respect of fermentation performance, storage stability, acid and bile resistance, and the effect on treating metabolic diseases.

Abstract: The present disclosure belongs to the technical field of medicine, and relates to a use of a GABAA receptor as a target in the preparation or screening of a drug for reducing blood lipid, treating obesity, and/or improving metabolism. The present disclosure provides a use of a GABAA receptor as a target in the preparation or screening of a drug with one or more functions selected from the group consisting of functions (1) to (4): (1) reducing blood lipid; (2) treating obesity; (3) improving metabolic syndrome; and (4) inhibiting small intestinal lipid absorption. The GABAA receptor is closely related to a lipid absorption ability of a small intestine, and the use of the present disclosure provides a new drug target and a new therapeutic means for treating obesity, reducing blood lipid, and improving metabolism.

Abstract: A robot for pond desilting is provided, which includes a frame, a lead screw sliding table, and a suction pipe. An end of the frame is provided with a pressure-resistant cabin. A lead screw base is disposed on the lead screw sliding table. A rotary lead screw is disposed on the lead screw sliding table. The lead screw base is disposed on the rotary lead screw. Waterproof motors are disposed above the lead screw base, a pump body is disposed in the frame, and the suction pipe is disposed at an end of the pump body. When the robot is placed at the bottom of the pond, the motor inside the pressure-resistant cabin drives the power wheels to rotate, the power wheels drive the tracks to rotate around the power wheels, bearing wheels, and tension wheels, thereby driving the frame to move.

Abstract: Provided are an Akkermansia muciniphila strain and use thereof in preventing and treating metabolic diseases. This strain is named Akkermansia muciniphila SSYD-3 and the accession number thereof is CGMCC No. 14764. This strain is more ideal than the existing Ackermannia strain ATCC BAA835 in respect of fermentation performance, storage stability, acid and bile resistance, and the effect on treating metabolic diseases.

Abstract: Provided are uses of Bacteroides in preparation of a medicament. The medicament is for use in treatment or prevention of obesity and obesity-related diseases. Also provided are a pharmaceutical composition, a medicament, a food product, and an animal feed that comprise Bacteroides, uses thereof in treatment or prevention of obesity and obesity-related diseases, and a method for treatment or prevention of obesity and obesity-related diseases.

Abstract: An intestinal microorganism metagenomic feature is a bacteroid intestinal pattern. By using the intestinal metagenomic pattern, it was found that type 2 diabetic patients with different intestinal parasitic bacterial flora had remarkably different responses to treatment with the diabetic hypoglycemic drug acarbose. Therefore, before treatments, the intestinal patterns of the patients can be assessed to select those patients likely to experience optimal curative effects, and to determine whether acarbose is suitable for the treatment of individual patients with type 2 diabetes. In addition, while intestinal patterns are conventionally distinguished by DNA sequencing or PCT amplification of parasitic bacteria in excrements, the intestinal patterns can be well distinguished using a bile acid composition, especially secondary bile acids, under baseline conditions. The intestinal patterns can be identified through markers in blood, and then be used as markers for diagnosis.

Abstract: Provided are uses of Bacteroides in preparation of a medicament. The medicament is for use in treatment or prevention of obesity-related diseases. Also provided are a pharmaceutical composition, a medicament, a food product, and an animal feed that comprise Bacteroides, uses thereof in treatment or prevention of obesity-related diseases, and a method for treatment or prevention of obesity-related diseases.

Abstract: Provided are uses of Bacteroides in preparation of a medicament. The medicament is for use in treatment or prevention of obesity and obesity-related diseases. Also provided are a pharmaceutical composition, a medicament, a food product, and an animal feed that comprise Bacteroides, uses thereof in treatment or prevention of obesity and obesity-related diseases, and a method for treatment or prevention of obesity and obesity-related diseases.